BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

762 related articles for article (PubMed ID: 10955821)

  • 1. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
    Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
    Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2.
    Schmidt M; McWatters A; White RA; Groner B; Wels W; Fan Z; Bast RC
    Gynecol Oncol; 2001 Feb; 80(2):145-55. PubMed ID: 11161852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.
    Zhou XX; Ji F; Zhao JL; Cheng LF; Xu CF
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1266-75. PubMed ID: 20594254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
    Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
    Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
    Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
    Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
    Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
    Pietras RJ; Poen JC; Gallardo D; Wongvipat PN; Lee HJ; Slamon DJ
    Cancer Res; 1999 Mar; 59(6):1347-55. PubMed ID: 10096569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
    Griffin T; Raso V
    Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human tumor growth by intraperitoneal immunotoxins in nude mice.
    Marks A; Ettenson D; Bjorn MJ; Lei M; Baumal R
    Cancer Res; 1990 Jan; 50(2):288-92. PubMed ID: 2295069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts.
    Ng B; Kramer E; Liebes L; Wasserheit C; Hochster H; Blank E; Ceriani R; Furmanski P
    Cancer Res; 2001 Apr; 61(7):2996-3001. PubMed ID: 11306478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
    Ramakrishnan S; Houston LL
    Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer.
    FitzGerald DJ; Bjorn MJ; Ferris RJ; Winkelhake JL; Frankel AE; Hamilton TC; Ozols RF; Willingham MC; Pastan I
    Cancer Res; 1987 Mar; 47(5):1407-10. PubMed ID: 3493065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
    Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
    Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human T-cell tumor growth by T101-ricin A-chain in an athymic mouse model.
    Leonard JE; Johnson DE; Shawler DL; Dillman RO
    Cancer Res; 1988 Sep; 48(17):4862-7. PubMed ID: 3261627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
    Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
    Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Synergistic antitumor activity of human breast cancer immunotoxins].
    Yu YH
    Zhonghua Zhong Liu Za Zhi; 1990 Jul; 12(4):246-50. PubMed ID: 2272257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
    Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
    Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
    Bianco C; Bianco R; Tortora G; Damiano V; Guerrieri P; Montemaggi P; Mendelsohn J; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2000 Nov; 6(11):4343-50. PubMed ID: 11106252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.